Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
- 1 August 2000
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 26 (5) , 474-479
- https://doi.org/10.1053/ejso.1999.0925
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Comparison of Preoperative Serum CA19-9 Levels with Results of Diagnostic Imaging Modalities in Patients Undergoing Laparotomy for Suspected Pancreatic or Gallbladder DiseasePancreas, 1994
- Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.Gut, 1994
- CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory studyClinica Chimica Acta; International Journal of Clinical Chemistry, 1992
- The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patientsCancer, 1988
- Elevated serum levels of tumor marker CA19-9 in acute cholangitisDigestive Diseases and Sciences, 1988
- Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreasGastroenterology, 1986
- New carbohydrate tumor markersGastroenterology, 1986
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984
- Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.Journal of Clinical Pathology, 1984
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979